SEOUL, November 14 (AJP) - Shares of South Korean biotech company ABL Bio rose 6.5 percent Friday to 174,200 won ($119), extending a three-day rally that has propelled the stock into the top tier of the local market.
At one point during trading, the stock jumped more than 17 percent.
The surge follows ABL Bio’s announcement Wednesday of a major licensing agreement with U.S. pharmaceutical giant Eli Lilly. The deal, which could ultimately be worth up to 3.8 trillion won ($2.6 billion), is the third-largest technology transfer agreement in South Korea’s history.
Under the terms, ABL Bio will receive a $40 million upfront payment and up to $2.56 billion in milestone payments, along with tiered royalties on future product sales.
The stock gained 30 percent Wednesday and added 29 percent Thursday, reflecting investor enthusiasm over the high-profile partnership. Eli Lilly, based in Indianapolis, is one of the world’s most valuable pharmaceutical companies and ranks 100th on the Fortune 500 and 138th on the Forbes Global 2000.
Kyobo Securities analyst Jung Hee-ryeong raised her target price for the company to 190,000 won and assigned a “buy” rating, noting that ABL Bio is “on track to reach 10 trillion won ($6.85 billion)” in market capitalization. As of Friday’s close, the company’s market cap stood at 9.6 trillion won ($6.56 billion), just shy of that milestone.
Jung highlighted several upcoming catalysts for the stock.
The company’s Grabody-B platform has already generated 9.2 trillion won in cumulative deals, and positive interim results from a Phase 2 clinical trial expected in 2026 could further boost its valuation. A joint study with Ionis Pharmaceuticals assessing the platform’s muscle-delivery potential is scheduled for publication in December, potentially expanding the platform’s perceived versatility.
Additional drivers include new licensing agreements, data from ABL001’s bile duct cancer treatment, and accelerated approval filings expected in the first half of next year.
Korea’s broader biotech sector has also gained momentum. The KRX Healthcare Index, which tracks 66 pharmaceutical and biotech companies, has risen 9 percent so far this month, outperforming the KRX Semiconductor Index, which gained 1.6 percent.
Analysts expect the biotech rally to extend into early 2026, supported by deal activity, clinical trial updates, and the potential for U.S. interest rate cuts. Korea Investment & Securities recommended a range of firms with licensing potential — including LigandChem Bio, D&D Pharmatech, Hanmi Pharmaceutical, AprilBio, and Kolon TissueGene — alongside ABL Bio.
“The ABL Bio–Eli Lilly deal revived investor confidence in Korean biotech firms’ global competitiveness,” said Wi Hae-joo, an analyst at Korea Investment & Securities.
Copyright ⓒ Aju Press All rights reserved.
